Brazil conditionally clears Takeda drug portfolio purchase

Brazil’s competition authority has greenlit local drugmaker Hypera Pharma’s bid to purchase a portfolio of medications from Takeda Pharmaceutical after the company offered a “fix-it-first” structural remedy.


Get unlimited access to all Global Competition Review content